MOTS-c common uses, half-life, side effects and more

MOTS-c is a 16-amino-acid peptide whose gene sits inside mitochondrial DNA. People inject it for insulin sensitivity, exercise capacity, and longevity goals. No regulator has approved it anywhere and no completed study has ever given it to a person. Vials sold online are research-market material with almost no independent testing behind them. Anyone tested in sport should know it is banned by name all year round.

• Insulin sensitivity and metabolic flexibility
• Exercise capacity and fatigue resistance
• Body composition support during a calorie deficit
• Longevity and mitochondrial health protocols

Daily to twice weekly in blocks of four to ten weeks

Reported doses run from about 0.5 to 5 mg injected under the skin. People take them daily to twice a week for roughly 1.5 to 15 mg across a week. There is no settled protocol and users openly disagree about whether small daily doses beat larger ones twice weekly. One forum's own pinned guide starts at 200 to 1,000 mcg daily, below what many posters describe running. Some switch to a whole 10 mg vial into muscle to escape skin reactions rather than for any dosing reason. A widely copied schedule of 5 mg every five days began on a vendor affiliate page in 2022 and no first-hand user runs it. The animal doses behind the popular claims scale to roughly 20 to 600 mg a week in an adult.

• A 10 mg vial in 1 mL of water makes 2 mg read as 20 units and 5 mg as 50 units on an insulin syringe
• Experienced users tell newcomers to start low and keep antihistamines on hand because of the skin reactions
• Blocks of four to ten weeks are more common than continuous use
• A purity certificate says how much of one compound is in a vial rather than which compound it is
• Only mass spectrometry confirms a vial holds the right 16-amino-acid sequence

Nobody has measured how long injected MOTS-c lasts in people or in any animal. The one to two hour figure that circulates was inferred from how fast the body clears peptide it released itself after exercise. Vendor pages also give 45 minutes, two to four hours, and four to five days. Those cannot all be true.

• Itchy welts and lumps at the injection site are the most reported problem and several people describe them lasting a week
• Histamine-type reactions appear repeatedly in first-hand accounts and one person described a near-anaphylactic response
• Raised heart rate, palpitations, insomnia, and fever are the four effects an anti-doping agency collected from uncontrolled self-reports
• Fatigue, headache, and flu-like symptoms circulate on vendor pages and trace back to no source at all
• Blood sugar fell about 6 percent over four weeks in the only human study of a related molecule

The gene for MOTS-c sits inside the 12S ribosomal RNA gene of mitochondrial DNA. The peptide cannot be built inside the mitochondrion itself. Human mitochondria carry no transfer RNA that reads two of its codons. The instructions must therefore reach the main body of the cell and nobody has shown how that happens. Adding the peptide switches on an energy sensor called AMPK. A Copenhagen group with no ties to the discovering laboratory confirmed the effect needs AMPK present to work. A 2015 experiment proposed that MOTS-c blocks a folate pathway until a natural AMPK trigger builds up. Nobody has measured that step again since, including the laboratory that proposed it. A 2024 paper from that same laboratory named a different primary target and did not mention AMPK anywhere. No cell-surface receptor has been found.

Nobody has completed a study giving MOTS-c to a person. A 2026 FDA review found no toxicity study, no reproductive or cancer testing, and no measurement of how the peptide behaves in a living body. That review also states the molecular targets remain unknown. The one human trial in this family used a different engineered molecule, ran four weeks, never reached a journal, and left both its antibody and its pharmacokinetic results unpublished before the company dissolved. Rodent work on glucose handling, exercise capacity, and muscle function is real and has been repeated in several countries. The human studies measure only the peptide people already make. An accredited doping laboratory could not confirm the antibody test that nearly all of them rely on. Reported blood levels across the literature differ by about four orders of magnitude. A registered trial of the peptide appeared in 2026 under a seller whose registry account also holds an admitted mock protocol.

• MOTS-c is named on the anti-doping prohibited list, is banned in and out of competition all year, and sits in a class with no reduced-sanction route for accidental use
• Injecting a peptide the body already makes can raise antibodies against the body's own supply and the FDA named this its main concern
• Whether MOTS-c helps or harms aging cells is unsettled and reviews group it with its sibling peptide as a pathway tumors could exploit
• No toxicity, fertility, pregnancy, or cancer study of any kind has been done
• Vials carry almost no independent identity testing and a purity number does not prove what is inside
• There is no lawful route to MOTS-c through a US compounding pharmacy